<DOC>
	<DOC>NCT01127750</DOC>
	<brief_summary>This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.</brief_summary>
	<brief_title>Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1865 years of age, must have relapsing MS Patients with a type of MS that is not relapsing Patients with history of chronic immune disease Patients with a history of certain cancers Diabetic patients with certain eye disorders Patients who are on certain immunosuppressive medications or heart medications Patients with certain heart conditions Patients with certain lung conditions Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>health outcomes</keyword>
</DOC>